Generic Name: Nusinersen
Brand Name: Spinraza
Manufacturer: Biogen Canada Inc.
Indications: Spinal Muscular Atrophy
Manufacturer Requested Reimbursement Criteria1:
That nusinersen be reimbursed for the treatment of 5q Spinal Muscular Atrophy (SMA) [including presymptomatic, Types I, II and III patients].
Submission Type: Resubmission
Project Status: Pending
Call For Patient Input: June 22, 2018
Patient Input Closed: August 14, 2018
Anticipated Date: July 23, 2018
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
genetics, nervous system, pediatrics, musculoskeletal